Treace Medical Concepts (TMCI) EBIT (2020 - 2026)

Treace Medical Concepts (TMCI) has reported EBIT for 7 consecutive years, with -$15.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 11.88% year-over-year to -$15.0 million; the trailing twelve-month figure through Jun 2026 stood at -$53.7 million (down 12.17% YoY), and the FY2025 full-year result was -$54.2 million, up 2.75% from the prior year.
• EBIT rose to -$15.0 million in Q2 2026 per TMCI's latest filing, from -$17.2 million in the prior quarter.
• Across five years, EBIT topped out at -$204000.0 in Q4 2024 and bottomed at -$21.4 million in Q2 2024.
• Historically, EBIT has averaged -$12.7 million across 5 years, with a median of -$14.4 million in 2023.
• The sharpest annual moves came in 2024 and 2025: EBIT surged 96.99% in 2024, then plunged 2802.94% in 2025.
• Over 5 years, EBIT stood at -$3.5 million in 2022, then tumbled by 93.94% to -$6.8 million in 2023, then soared by 96.99% to -$204000.0 in 2024, then slumped by 2802.94% to -$5.9 million in 2025, then slumped by 152.58% to -$15.0 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$15.0 million, -$17.2 million, and -$5.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.